期刊文献+

噻唑烷二酮类药物的作用机理和临床评价 被引量:1

下载PDF
导出
作者 王焕杰
出处 《中国民康医学》 2006年第19期880-882,共3页 Medical Journal of Chinese People’s Health
  • 相关文献

参考文献16

  • 1余自成,卢怒.口服降糖药的合理选用[J].中国临床药学杂志,2000,9(1):60-62. 被引量:10
  • 2Glass CK, Rosenfeld MG. The coregulator exchange in transcriptional function of nuclear receptors[J]. Genes Dev,2000,14 : 121- 141.
  • 3Gillies PS, Dunn CJ. Pioglitazone. Drugs,2000,60:333 - 343.
  • 4Burris TP, Pelton PD, Zhou L, et al. A novel methodforanalysis of nuclear receptor function at natural promoters : peroxisome proliferators - activated receptorgamma agonist actions on aP2 gene expressiondetected using branched DNA messenger RNA quantitation[J]. Mol Endocrinol,1999,13:410 -417.
  • 5Rosenbaum SE,Greenberg AS. The short- and long -termeffects of tumor necrosis factor - alpha and BRL 49653 on peroxisome proliferators-actived receptor(PPAR) gamma2 gene expression and adipocyte genes[J]. Mol Endocrinol, 1998,12 : 1150 - 1160.
  • 6张喆.噻唑烷二酮类药物治疗2型糖尿病的机理与评价[J].辽宁实用糖尿病杂志,2002,10(1):13-15. 被引量:9
  • 7Bulforu JA, Plosker GL. Rosiglitazone [ J ]. Drugs, 1999,57 ( 6 ) :921.
  • 8Spencer CM, Murkham A. Troglitazone [ J]. Drugs, 1997,54 ( 1 ) :89.
  • 9Iwumoto Y, Kosaka K, kuzuya T, et al. Effectsoftroglitazone [J]. DiabetesCare, 1996,19 ( 2 ) : 151.
  • 10邓宏明,于志清,夏宁,肖常青,李世生,黎英荣,苏宏业,梁瑜贞,覃忠.胰岛素增敏剂罗格列酮治疗2型糖尿病的临床疗效观察[J].广西医科大学学报,2000,17(5):805-807. 被引量:10

二级参考文献21

  • 1征革凡,王金平,张辉,胡泽溪,刘娟,肖建中,陈仕明,曹辉碧,李光伟,胡英华,潘孝仁.拜糖平治疗非胰岛素依赖型糖尿病的临床观察[J].中华内分泌代谢杂志,1995,11(3):163-164. 被引量:43
  • 2Spiegelman BM. PPAR - y, Adipogenic regultor and thiazolidinedione receptor.Diabetes 1998,284:751-759.
  • 3Schoonjans K, Martin G, Staels B, et al. Peroxisome proliferator-activated receotors, orphans with ligands and functions.Curr Opin Lipidol 1997,8:159-166.
  • 4Digyb JE, Montague CT, Stewter CP, et al. Thiazolidinediones exposure increases the expression of uncoupling protein 1 in cultured human preadipocytes. Diabetes 1998,47:138-141.
  • 5Nomura, Kinoshita S. Thiaolidine2, 4 - diones as structurally new Antihyperglycemic agents. Bioorg Med Chem Lett 1999,9:533-538.
  • 6Shibuya A, Wantanabe M, Fujita Y, et al. An autopaycase of troglitazone - induced funlminant hypatitis. Diabetes Care 1998,21:2140-2143.
  • 7Elcock FJ, Lyon JJHitchcock J, et al. Toxicity of troglitazone in cultured rat hepatiocytes. Weir GC, Diabetes - 59th Ann Sci Sessions. USA: The American Diabetes Association 1999,A63.
  • 8Saltidel All, Olefsky J. Thiaolidinediones in the treatment of insulin resistance and type 2 diabetes. Diabetes 1996,45:1661-1667.
  • 9Scheen AJ. Drug treatment of non-insulin-dependent diabetes mellitus In the 1990s' achivements and funture developments. Drugs 1997,54:355-358.
  • 10Kreider M, Miller E, Petel J. Rosiglitazone is sage and well tolerated as monotherapy or combination therapy in patient with type 2 diabetes Mellitus. Poster accepted for American Diabetes Association Meeting 1999,19-22, San Diego.

共引文献70

同被引文献7

引证文献1

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部